Global AI in Antibody Discovery Market Size, Share, Trends & Growth Analysis Report 2026-2034

Description

The global AI in antibody discovery market size is expected to reach USD 6.60 Billion in 2034 from USD 0.90 Billion in 2025, growing at a CAGR of 24.77% during 2026-2034.This market is expanding as pharmaceutical and biotechnology companies use artificial intelligence to accelerate the identification and optimization of therapeutic antibodies. Traditional antibody discovery can require extensive laboratory screening and iterative optimization. AI systems can analyze biological datasets, predict molecular interactions, identify promising antibody candidates, and support sequence optimization. Growing investment in biologics development is therefore creating demand for computational tools capable of reducing discovery bottlenecks and helping researchers evaluate larger numbers of potential candidates.

Machine learning and generative AI are increasingly being applied to antibody sequence design, structure prediction, affinity optimization, and developability assessment. These capabilities can complement laboratory experiments by prioritizing candidates before extensive experimental testing. Biotechnology companies are also using computational platforms to analyze immune repertoires and identify antibody candidates against challenging targets. As datasets expand, AI models can potentially improve their ability to identify relationships between antibody sequence, structure, binding characteristics, and other development-relevant properties.

Future prospects are supported by continued investment in biologics, precision medicine, and computational drug discovery. AI platforms are expected to become more integrated with laboratory automation, protein-structure analysis, and experimental validation workflows. Improvements in model quality and access to high-quality biological datasets could broaden their usefulness across antibody development. However, experimental validation remains essential because computational predictions do not independently establish clinical effectiveness or safety. Companies combining AI capabilities with strong biological expertise and laboratory infrastructure can participate in an expanding discovery ecosystem.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Offering

Software Platforms
Discovery Services
Integrated Platform Partnerships
Data and Model Licensing

By Technology

Structure Prediction
Generative AI and Protein Language Models
Machine Learning and Deep Learning
Natural Language Processing and Knowledge Graphs
Closed-Loop AI with Lab Automation

By Application

Target Identification and Validation
Epitope Mapping and Binder Screening
De Novo Antibody Design
Lead Optimization and Engineering
Developability and Manufacturability Prediction

By Antibody Modality

Monoclonal Antibodies
Bispecific Antibodies
Multispecific Antibodies
Antibody-Drug Conjugates
Nanobodies and Single-Domain Antibodies

By Therapeutic Area

Oncology
Autoimmune and Inflammatory Diseases
Infectious Diseases
Neurology
Metabolic Diseases
Rare Diseases

By End User

Pharmaceutical Companies
Biotechnology and Platform Companies
CROs and CDMOs
Academic and Research Institutes

COMPANIES PROFILED

AbCellera, Absci, Alloy Therapeutics, Antiverse, BigHat Biosciences, Chai Discovery, Cradle, Etcembly, EVQLV, Generate:Biomedicines, Harbour BioMed, Infinimmune, Insilico Medicine, LabGenius Therapeutics, MAbSilico, MOLCURE, Nabla Bio, Nona Biosciences

Product Code: VMR112118301

Chapter 1. PREFACE

1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis

Chapter 4. GLOBAL AI IN ANTIBODY DISCOVERY MARKET: BY OFFERING 2022-2034 (USD MN)

4.1. Market Analysis, Insights and Forecast Offering
4.2. Software Platforms Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Discovery Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. Integrated Platform Partnerships Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.5. Data and Model Licensing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL AI IN ANTIBODY DISCOVERY MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

5.1. Market Analysis, Insights and Forecast Technology
5.2. Structure Prediction Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. Generative AI and Protein Language Models Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.4. Machine Learning and Deep Learning Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.5. Natural Language Processing and Knowledge Graphs Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.6. Closed-Loop AI with Lab Automation Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL AI IN ANTIBODY DISCOVERY MARKET: BY APPLICATION 2022-2034 (USD MN)

6.1. Market Analysis, Insights and Forecast Application
6.2. Target Identification and Validation Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Epitope Mapping and Binder Screening Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.4. De Novo Antibody Design Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.5. Lead Optimization and Engineering Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.6. Developability and Manufacturability Prediction Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL AI IN ANTIBODY DISCOVERY MARKET: BY ANTIBODY MODALITY 2022-2034 (USD MN)

7.1. Market Analysis, Insights and Forecast Antibody Modality
7.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.3. Bispecific Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.4. Multispecific Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.5. Antibody-Drug Conjugates Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.6. Nanobodies and Single-Domain Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL AI IN ANTIBODY DISCOVERY MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

8.1. Market Analysis, Insights and Forecast Therapeutic Area
8.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
8.3. Autoimmune and Inflammatory Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
8.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
8.5. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
8.6. Metabolic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
8.7. Rare Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL AI IN ANTIBODY DISCOVERY MARKET: BY END USER 2022-2034 (USD MN)

9.1. Market Analysis, Insights and Forecast End User
9.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
9.3. Biotechnology and Platform Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
9.4. CROs and CDMOs Estimates and Forecasts By Regions 2022-2034 (USD MN)
9.5. Academic and Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL AI IN ANTIBODY DISCOVERY MARKET: BY REGION 2022-2034 (USD MN)

10.1. Regional Outlook
10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 10.2.1 By Offering
- 10.2.2 By Technology
- 10.2.3 By Application
- 10.2.4 By Antibody Modality
- 10.2.5 By Therapeutic Area
- 10.2.6 By End User
- 10.2.7 United States
- 10.2.8 Canada
- 10.2.9 Mexico
10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 10.3.1 By Offering
- 10.3.2 By Technology
- 10.3.3 By Application
- 10.3.4 By Antibody Modality
- 10.3.5 By Therapeutic Area
- 10.3.6 By End User
- 10.3.7 United Kingdom
- 10.3.8 France
- 10.3.9 Germany
- 10.3.10 Italy
- 10.3.11 Spain
- 10.3.12 Russia
- 10.3.13 Rest Of Europe
10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 10.4.1 By Offering
- 10.4.2 By Technology
- 10.4.3 By Application
- 10.4.4 By Antibody Modality
- 10.4.5 By Therapeutic Area
- 10.4.6 By End User
- 10.4.7 China
- 10.4.8 Japan
- 10.4.9 South Korea
- 10.4.10 India
- 10.4.11 Australia
- 10.4.12 South East Asia
- 10.4.13 Rest Of Asia Pacific
10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 10.5.1 By Offering
- 10.5.2 By Technology
- 10.5.3 By Application
- 10.5.4 By Antibody Modality
- 10.5.5 By Therapeutic Area
- 10.5.6 By End User
- 10.5.7 Brazil
- 10.5.8 Argentina
- 10.5.9 Peru
- 10.5.10 Chile
- 10.5.11 Rest of Latin America
10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 10.6.1 By Offering
- 10.6.2 By Technology
- 10.6.3 By Application
- 10.6.4 By Antibody Modality
- 10.6.5 By Therapeutic Area
- 10.6.6 By End User
- 10.6.7 Saudi Arabia
- 10.6.8 UAE
- 10.6.9 Israel
- 10.6.10 South Africa
- 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

11.1. Recent Developments
11.2. Company Categorization
11.3. Supply Chain & Channel Partners (based on availability)
11.4. Market Share & Positioning Analysis (based on availability)
11.5. Vendor Landscape (based on availability)
11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL AI IN ANTIBODY DISCOVERY INDUSTRY

12.1. Top Companies Market Share Analysis
12.2. Company Profiles
- 12.2.1 AbCellera
- 12.2.2 Absci
- 12.2.3 Alloy Therapeutics
- 12.2.4 Antiverse
- 12.2.5 BigHat Biosciences
- 12.2.6 Chai Discovery
- 12.2.7 Cradle
- 12.2.8 Etcembly
- 12.2.9 EVQLV
- 12.2.10 Generate:Biomedicines
- 12.2.11 Harbour BioMed
- 12.2.12 Infinimmune
- 12.2.13 Insilico Medicine
- 12.2.14 LabGenius Therapeutics
- 12.2.15 MAbSilico
- 12.2.16 MOLCURE
- 12.2.17 Nabla Bio
- 12.2.18 Nona Biosciences